Key Takeaway: BioMarin Pharmaceutical Inc. has announced its participation in four investor conferences scheduled for March 2026. These events include the TD Cowen 46th Annual Health Care Conference, the Leerink 2026 Global Healthcare Conference, the Jefferies 2026 Biotech on the Bay Summit, and the Barclays 28th Annual Global Healthcare Conference. The company will provide live webcasts of the discussions, which will also be available for replay on their website.
Price reaction · baseline $62.92 (2026-02-23 close) · hit pre-market · clean, no other BMRN news in the window
day 0 close
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
BioMarin is actively engaging with investors through multiple conferences.
The company has a strong track record of innovation in rare diseases.
Webcast replays will be available, enhancing accessibility for investors.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
7.9%
average across 8 past catalysts
Lead asset
Valoctocogene roxaparvovec
Phase 3 · Hemophilia A
Full Press Release Details
SAN RAFAEL, Calif.,Feb. 24, 2026/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced management will participate in four upcoming investor conferences in March.
TD Cowen 46th Annual Health Care Conference
(Boston, MA)
Leerink 2026 Global Healthcare Conference
(Miami, FL)
Jefferies 2026 Biotech on the Bay Summit (Miami, FL)
Barclays 28thAnnual Global Healthcare Conference (Miami, FL)
The fireside chats will be webcast live and can be accessed by visiting BioMarin's website athttps://investors.biomarin.com/. A webcast replay will be available through the Company's website for a limited time following the conferences.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with multiple commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visitwww.biomarin.com.
Contacts:
Investors
Media
Traci McCarty
Marni Kottle
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558
(650) 374-2803
Frequently Asked Questions
Which conferences will BioMarin participate in March?
BioMarin will participate in four conferences: TD Cowen, Leerink, Jefferies, and Barclays.
Where can I watch the BioMarin conference webcasts?
The webcasts can be accessed on BioMarin's investor website.
What is BioMarin known for?
BioMarin specializes in developing medicines for genetically defined rare diseases.
When were the investor conferences announced?
The investor conferences were announced on February 24, 2026.